Creating a new inhalable treatment for lung scarring diseases
Development, Formulation and Inhalational Delivery of a New Peptide for ILD
This study is looking at a new inhalable treatment for interstitial lung diseases like idiopathic pulmonary fibrosis, which causes serious lung damage, to see if a special peptide can help protect lung cells and slow down the disease.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas Hlth Ctr at Tyler NIH-funded |
| Lab location | 1 site (Tyler, United States) |
| Project ID | NIH-10745673 on NIH RePORTER |
What this research studies
This research focuses on developing a new peptide that can be inhaled to treat interstitial lung diseases (ILDs), particularly idiopathic pulmonary fibrosis (IPF), which causes severe lung scarring and has no cure. The approach involves understanding how certain proteins affect lung cell health and using a specific peptide to inhibit harmful processes that lead to cell death and fibrosis. By testing this peptide in preclinical models, the researchers aim to find a more effective treatment that could slow or stop the progression of this debilitating disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with idiopathic pulmonary fibrosis or other forms of interstitial lung disease.
Not a fit: Patients with other types of lung diseases not related to interstitial lung disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a novel inhalable therapy that significantly improves lung function and quality of life for patients with IPF.
How similar studies have performed: Previous research has shown promise in developing peptide-based therapies for lung diseases, indicating potential for success in this novel approach.
Where this research is happening
Tyler, United States
- University of Texas Hlth Ctr at Tyler — Tyler, United States (Active)
Researchers
- Principal investigator: Shetty, Sreerama — University of Texas Hlth Ctr at Tyler
- Study coordinator: Shetty, Sreerama
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.